susan-froshauer-150px_w_outline

David Scheer, M.S.
CURE Board of Directors

David Scheer is President of Scheer & Company, Inc., a firm founded in 1981, with activities in venture capital, corporate strategy, and transactional advisory services focused on the life sciences. Mr. Scheer was involved in the founding and had been a member of the Boards of Directors of ViroPharma, Inc. (NASDAQ, “VPHM”), OraPharma, Inc. (acquired by Johnson & Johnson in 2003), and Esperion Therapeutics, Inc. (of which he was Chairman, acquired by Pfizer in 2004). His current board relationships include Achillion Pharmaceuticals, Inc. (of which he is Chairman, NASDAQ, “ACHN”), Aegerion Pharmaceuticals, Inc. (of which he is Chairman, NASDAQ, “AEGR”), Tengion, Inc. (of which he is Chairman, OTC BB, “TNGN”) Axerion Therapeutics, Inc. (of which he is Chairman), and Optherion, Inc. (of which he is Chairman).

From 1991 through 1999, he was affiliated with the health care investing team at Oak Investment Partners. Mr. Scheer has also led or played a significant role in a series of transactions involving corporate alliances, licensing arrangements, divestments, acquisitions and mergers in the life sciences. He has served as a member of the Leadership Council of the Harvard School of Public Health, and as a member of the Advisory Committee to the Harvard Malaria Initiative.

He has helped to launch, and served as Chair of the Executive Committee for “The Unfinished Agenda in Infectious Diseases”, an initiative at the Harvard School of Public Health focusing on the neglected diseases. He has also been a member of the Global Advisory Council for AIDS@30, an initiative at Harvard, and an Advisor for the Global Task Force for Expanding Cancer Care and Control in the Developing World, another Harvard-affiliated initiative. He also serves as an advisor to the Rett Syndrome Research Trust. Since 2003, he has been a member of the Board of Trustees, and Vice-Chair for the Long Wharf Theatre, in New Haven, CT.

He is the founding Chair of the Global Health and the Arts series in New Haven, which for the past 5 years has been a collaboration between Long Wharf and Yale. In 2007, he was awarded the Atlas Award for Venture Capital from CURE, of which he also serves as a member of the Board and is on the Executive Committee), and in 2009, he received the Venture CapitalLeadership Award from the Connecticut Venture Group. In 2013, he was the recipient of the Yale Science and Engineering Association Award for Distinguished Service to Industry, Commerce, and Education.

He received his A.B. cum laude in Biochemical Sciences from Harvard College, and an M.S. in Cell, Molecular and Development Biology, from Yale University.